Senior Medical Director
Iambic Therapeutics, Inc · Astellas Pharma Global Development, Inc. · Sinovac Biotech Co., Ltd
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
66
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in non-small cell lung cancer
0
PubMed author-name match
Trials
Studies that name Senior Medical Director as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:17 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06253871 · A Phase 1/1b Study of IAM1363 in HER2 CancersIambic Therapeutics, Inc · recruiting · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer · study director
- Ph1NCT05646797 · A Study of ASP2074 in Adults With Solid TumorsAstellas Pharma Global Development, Inc. · terminated · Advanced Solid Tumors · study director
- Ph3NCT05431725 · Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, QuadrivalentSinovac Biotech Co., Ltd · completed · Seasonal Influenza · study director
- Ph1NCT04942964 · A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic FunctionAstellas Pharma Global Development, Inc. · completed · Hepatic Impairment, Healthy Volunteers · study director
- Ph1NCT04855201 · A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen ExtractionAstellas Pharma Global Development, Inc. · terminated · Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction · study director
- Ph2NCT04641962 · A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial MyopathyAstellas Pharma Inc · terminated · Primary Mitochondrial Myopathy · study director
- Ph1NCT04184895 · A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust MitesAstellas Pharma Global Development, Inc. · active not recruiting · Allergic to House Dust Mites · study director
- Ph1NCT03960489 · A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult SubjectsAstellas Pharma Global Development, Inc. · completed · Healthy Adult Subjects · study director
- Ph2NCT03760081 · A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell TumorsAstellas Pharma Global Development, Inc. · completed · Incurable Platinum Refractory Germ Cell Tumors, Tumors · study director
- Ph1NCT03755713 · A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid VaccineAstellas Pharma Global Development, Inc. · completed · Peanut Allergy · study director
- Ph1NCT03356639 · A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With SchizophreniaAstellas Pharma Global Development, Inc. · completed · Schizophrenia · study director
- Ph1NCT03241550 · A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric PatientsAstellas Pharma Global Development, Inc. · completed · Hematological Malignancy · study director
- Ph1/Ph2NCT03092791 · IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and AdultsTakeda · terminated · Poliomyelitis · study director
- Ph1NCT03065959 · A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in MobilityAstellas Pharma Global Development, Inc. · terminated · Mobility Limitation · study director
- N/ANCT03066011 · Registry of Patients Treated With Systemic Mold-Active TriazolesAstellas Pharma Global Development, Inc. · completed · Invasive Fungal Infection · study director
- Ph2NCT03056690 · A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With FibromyalgiaAstellas Pharma Global Development, Inc. · completed · Fibromyalgia · study director
- Ph2NCT03042013 · A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 StudyAstellas Pharma Global Development, Inc. · withdrawn · Subjects With NSCLC With an EGFR Activating Mutation · study director
- Ph3NCT02997202 · A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)Astellas Pharma Global Development, Inc. · completed · Acute Myeloid Leukemia · study director
- Ph1NCT02867306 · A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid ArthritisAstellas Pharma Global Development, Inc. · completed · Rheumatoid Arthritis · study director
- Ph1NCT02851277 · A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid VaccineAstellas Pharma Global Development, Inc. · completed · Peanut Allergy · study director
- Ph1NCT02720263 · A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With SchizophreniaAstellas Pharma Global Development, Inc. · completed · Schizophrenia · study director
- Ph1NCT02698657 · A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on MethotrexateAstellas Pharma Global Development, Inc. · completed · Rheumatoid Arthritis (RA) · study director
- Ph1NCT02674555 · A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid TumorsAstellas Pharma Global Development, Inc. · withdrawn · Epidermal Growth Factor Receptor (EGFR) Mutations, Solid Tumors · study director
- Ph2NCT02662582 · A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary DiseaseAstellas Pharma Global Development, Inc. · completed · Chronic Obstructive Pulmonary Disease (COPD) · study director
- Ph1/Ph2NCT02495233 · A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)Astellas Pharma Global Development, Inc. · terminated · Non-Small-Cell Lung Cancer · study director
- Ph2NCT02372578 · Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral NeuropathyAstellas Pharma Global Development, Inc. · terminated · Painful Diabetic Peripheral Neuropathy (PDPN) · study director
- Ph1NCT02194491 · A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662Astellas Pharma Global Development, Inc. · completed · Pharmacokinetics of ASP3662, Displacement of Radiotracer, Healthy Volunteers · study director
- Ph1NCT02171143 · A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on MethotrexateAstellas Pharma Global Development, Inc. · completed · Rheumatoid Arthritis, Pharmacokinetics of ASP2409 · study director
- Ph1NCT02150070 · A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) InjectionsAstellas Pharma Global Development, Inc. · completed · Pharmacokinetics of ASP2408, Healthy Subjects · study director
- Ph1NCT02141425 · A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy SubjectsAstellas Pharma Global Development, Inc. · completed · Healthy Volunteers, Pharmacokinetics of ASP015K · study director
- Ph1NCT02128893 · A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of IsavuconazoleAstellas Pharma Global Development, Inc. · completed · Pharmacokinetics of Isavuconazole, Healthy Subjects · study director
- Ph1NCT02128321 · A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and CaffeineAstellas Pharma Global Development, Inc. · completed · Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine, Healthy Subjects · study director
- Ph1NCT02113813 · A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsAstellas Pharma Global Development, Inc. · completed · Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations · study director
- N/ANCT02066961 · A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate CancerAstellas Pharma Global Development, Inc. · completed · Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer · study director
- Ph1NCT02054351 · Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)Ganymed Pharmaceuticals GmbH · completed · Ovarian Cancer · study director
- Ph1NCT02052375 · A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on MethotrexateAstellas Pharma Global Development, Inc. · completed · Rheumatoid Arthritis, Pharmacokinetics of ASP2408 · study director
- Ph2NCT01982253 · Fasiglifam 25 mg BID vs 50 mg QDTakeda · terminated · Type 2 Diabetes Mellitus · study director
- Ph1NCT01918995 · Repeat Dose Tolerance Study of Regadenoson in Healthy SubjectsAstellas Pharma Global Development, Inc. · completed · Healthy Volunteers · study director
- Ph2NCT01883505 · A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease PatientsNeuroDerm Ltd. · completed · Parkinson's Disease · study director
- Ph1NCT01809860 · A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy SubjectsAstellas Pharma Global Development, Inc. · completed · Healthy Subjects, Pharmacokinetics of Isavuconazole, Pharmacokinetics of Sirolimus · study director
- Ph2NCT01780844 · A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant RecipientsAstellas Pharma Global Development, Inc. · completed · Kidney Transplantation · study director
- Ph2NCT01711814 · A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis StudyAstellas Pharma Global Development, Inc. · completed · Arthritis, Rheumatoid · study director
- Ph1NCT01711489 · A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult SubjectsAstellas Pharma Global Development, Inc. · completed · Healthy Subjects, Pharmacokinetics of Isavuconazole, Pharmacokinetics of Plasma Mycophenolic Acid (MPA) · study director
- Ph2NCT01663415 · A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerAstellas Pharma Global Development, Inc. · withdrawn · Metastatic Castration-Resistant Prostate Cancer · study director
- Ph3NCT01618669 · A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)Astellas Pharma Global Development, Inc. · completed · Coronary Artery Disease (CAD) · study director
- Ph2NCT01585233 · A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque PsoriasisAstellas Pharma Global Development, Inc. · completed · Psoriasis · study director
- Ph2NCT01565655 · A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid ArthritisAstellas Pharma Global Development, Inc. · completed · Arthritis, Rheumatoid · study director
- Ph2NCT01564862 · Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive DisorderTakeda · completed · Depressive Disorder, Major · study director
- Ph2NCT01554696 · A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to MethotrexateAstellas Pharma Inc · completed · Arthritis, Rheumatoid · study director
- Ph3NCT01549964 · Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 DiabetesTakeda · terminated · Glycemic Control · study director
- Ph1NCT01496443 · TAK-875 Glimepiride Drug-Interaction StudyTakeda · completed · Pharmacokinetics · study director
- Ph3NCT01481116 · Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 DiabetesTakeda · terminated · Diabetes Mellitus, Type 2 · study director
- Ph1NCT01476800 · A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult VolunteersAstellas Pharma Inc · completed · Healthy Subjects, Pharmacokinetics of YM178 · study director
- Ph3NCT01456195 · Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 DiabetesTakeda · completed · Diabetes Mellitus, Type 2 · study director
- Ph3NCT01364649 · Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual DysfunctionTakeda · completed · Treatment Outcome · study director
- Ph2NCT01334918 · A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)Astellas Pharma Inc · completed · Coronary Artery Disease (CAD) · study director
- Ph1NCT01320332 · A Study of a Single Dose of ASP3291 in Subjects With Ulcerative ColitisTelsar Pharma Inc. · completed · Ulcerative Colitis · study director
- Ph1NCT01284192 · Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)Astellas Pharma Inc · completed · Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS · study director
- Ph1NCT01279538 · A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney TransplantationAstellas Pharma Inc · completed · Kidney Transplantation · study director
- Ph3NCT01152996 · Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension StudyTakeda · completed · Depressive Disorder, Major · study director
- Ph2NCT01077284 · Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate StonesTakeda · completed · Hyperuricosuria, Kidney Stones · study director
- Ph2NCT01007292 · A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior TreatmentAstellas Pharma Inc · completed · Non-Hodgkin's Lymphoma · study director
- Ph3NCT00815516 · Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal CandidiasisAstellas Pharma Global Development, Inc. · terminated · Candidiasis · study director
- Ph2NCT00813527 · Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol LevelsTakeda · completed · Hyperlipidemias · study director
- Ph1NCT00608335 · Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the DrugAstellas Pharma Inc · completed · Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis · study director
- Ph2NCT00543569 · A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant RecipientsAstellas Pharma Inc · completed · Kidney Transplantation · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.